Comparing the current results to its competitors, Biomx Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Biomx Inc's competitors' average revenue growth of 10.54 %, achieved in the same quarter.
Biomx Inc, slower than the average decrease reported by the company's competitors of -97.25 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -97.25 %
Biomx Inc's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological advancements and strong competition. Competitors include larger pharmaceutical companies, specialty biotechnology firms, academic research institutions, governmental agencies, and other public and private organizations. Specific competitors developing bacteriophage products include Locus Biosciences, Inc., Armata Pharmaceuticals, Inc., SNIPR Biome, Technophage (developing TP-102), and Phaxiam. Many of these competitors possess greater financial, technical, and human resources, as well as more experience in product discovery, regulatory approval, and commercialization.
September 18, 2024
A New Frontier in Cystic Fibrosis Treatment: BiomX s Promising Data on BX004:In a significant development for cystic fibrosis (CF) management, BiomX Inc. a company at the forefront of phage therapy exploration, is set to present promising updates concerning its clinical trial on BX004. The findings will be featured at the North American Cystic Fibrosis Conference, underscoring the ongoing efforts to address chronic pulmonary infections caused by Pseudomonas aeruginosa a common and challenging pathogen among CF patients.BiomX Inc. is gaining attention for its innovative approach to treatment through engineered bacteriophage therapies. These therapies harness naturally occurring viruses that specifically tar...
April 23, 2024
BiomX, a leading industry pioneer in the employment of phage therapies in medicine, has announced that they will be presenting data from their groundbreaking Phase 1b/2a study of BX004 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The research provides valuable insight into the effects of this experimental treatment on patients suffering from cystic fibrosis chronic pulmonary infections. Moreover, this information is especially relevant because of its superior classification, as it has been chosen as a Top Poster, positioning it in the meritorious 1-2% of highest-rated abstracts in the category submitted and accepted at ECCMID 2024.This honor is a testament to the p...
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Sources:
Biomx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biomx Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
